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For patients with hematologic malignancies such as leuke-
mias, lymphomas and other related cancers, allogeneic
blood/marrow transplantation (allo BMT) is a critically
important therapy that can produce cures when chemo-
therapy alone cannot. More than 25,000 patients undergo
allo BMT world-wide each year. A major risk of allo BMT
continues to be graft-versus-host disease (GVHD), which
results from the donor immune system recognizing the
transplant recipient’s organs as foreign, leading to life-
threatening inﬂammation. Developing strategies that reduce
GVHD but leave global immune function intact should pro-
duce a major beneﬁt for patients.
One promising approach that we have developed is targeting
the complex community of microbes that reside within our
intestinal tracts, collectively termed the intestinal microbiota.Figure 1. Intestinal Blautia abundance predicts for GVHD in humans, A) A cohort of 1
intestinal GVHD, B) The same cohort stratiﬁed by Blautia abundance was evaluated f
Figure 2. Administration of Blautia to mice mitigates GVHD severity. A) B6 mice were
then inoculated 5 and 7 days later with Blautia or Enterococcus of murine origin, and
cells. Presented is overall survival, combined results from 2 experiments. B) Mice we
single experiment, mice harvested on BMT day 14 n¼4/group. C) Mice were treated wi
short chain fatty acid content by HPLC two weeks after bacterial introduction.While a relationship between the microbiota and GVHD has
been suspected for many years, it remains imperfectly un-
derstood. Gut decontaminationwith antibiotics is practiced at
some but not all centers, and there is no consensus regarding
ideal choice of antibiotic coverage.
Here we present results demonstrating that the abundance
of bacteria belonging to the genus Blautia, a commensal
commonly found in the intestinal tract of humans, predicts
for protection from life-threatening GVHD in allo BMT
patients (Figure 1). Furthermore, in murine models, intro-
ducing a species of Blautia of murine origin reduces GVHD
severity (Figure 2A). It appears to do so by inducing regula-
tory T cells with generation of short-chain fatty acid meta-
bolic byproducts (Figures 2B and 2C).
Additional studies characterizing the natural history of Blautia
abundance in allo BMT recipients demonstrate that the vast
majority of patients begin with abundant amounts of endog-
enous Blautia, but many lose their Blautia in a dramatic
fashion during the transplantation process (Figure 3A). Inter-
estingly, loss of Blautia correlates strongly with reductions in
oral nutritional intake in both humans and mice (Figures 3B
and 3C). Thus development of nutritional intervention stra-
tegies to support Blautia abundance following allo BMT could
potentially mitigate GVHD. In murine models we have found
that these nutritional approaches can successfully prevent
loss of Blautia as well as reduce severity GVHD.05 patients, stratiﬁed by abundance of Blautia, was evaluated for incidence of
or GVHD-related mortality.
treated orally with a 2 day course of vancomycin, a 2 day course of ampicillin,
then 2 weeks later irradiated and transplanted with B10.BR bone marrow and T
re treated as in A. Flow cytometric evaluation of T cell populations, results of a
th antibiotics and bacteria as in A but without BMT, and stool was evaluated for
Figure 3. Reduced nutritional intake appears to drive loss of Blautia in allo BMT recipients, A) Ninety-four allo BMT patients were evaluated weekly for changes in the
intestinal microbiota during transplant hospitalization. Blautia abundance is depicted by a solid black line with 95% conﬁdence bands shown in gray constructed
using moving average ﬁltering. B) Daily nutritional and microbiota analysis was collected in 5 allo BMT patients during transplant hospitalization, and abundance of
Blautia analyzed for stool samples stratiﬁed by kCal consumption. C) Stool abundance of Clostridials (the order to which Blautia belongs) was assayed in mice before
and after one week of 25% reduction m food consumption.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S22eS26 S23Our results have identiﬁed the microbiota as a potent ther-
apeutic target that can be recruited to signiﬁcantly reduce
GVHD. Approaches to potentially translate these ﬁndings
include investigating the safety of introduction of Blautia to
allo BMT recipients, or alternatively developing nutritional
strategies to support endogenous Blautia during the trans-
plantation process.
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Invariant natural killer T (iNKT) cells are a rare but potent
immunomodulatory subset of lymphocytes in humans (TCRa
Va24-Ja18) and mice (TCRa Va14-Ja18). It has been shown
previously that host iNKT cells require interaction with
CD4+FoxP3+ regulatory T cells to protect from acute GVHD
after conditioning with total lymphoid irradiation and anti-
thymocyte globulin (Pillai et al., Blood 2009). In this study, we
investigated the role of highly puriﬁed adoptively transferred
donor-derived CD4+ iNKT cells in the setting of myeloablative
conditioning. Balb/c (H-2Kd) recipient mice were irradiated
with 8 Gy and transplanted with T cell-depleted bonemarrow
together with 1x106 CD4/CD8 T lymphocytes (Tcon) from
C57Bl/6 (H-2Kb) donor mice. Mice co-injected with as low as
5x104 highly puriﬁed (>99%) CD4+ iNKT cells showed a sig-
niﬁcant survival beneﬁt compared to mice receiving Tcon
alone (p¼.002). Consistently, weight and GVHD score
improved in mice that received CD4+ iNKT cells. Signal in-
tensity derived from expanding luciferase expressing allor-
eactive Tcon was signiﬁcantly lower in animals treated with
CD4+ iNKT cells demonstrating inhibition of proliferation of
alloreactive Tcon through CD4+ iNKT cells (p<.0001). In vivo
CFSE proliferation assay conﬁrmed decreased Tcon prolifera-
tion in peripheral lymph nodes (p<.0001), mesenteric lymph
nodes (p¼.03) and spleen (p¼.0005). In addition, Tcon from
CD4+ iNKT cell treated mice showed a signiﬁcantly lowerexpression of activation markers CD44 and CD25. Interest-
ingly, animals treated with CD4+ iNKT cells showed a robust
expansion of donor-derived Neurophilin-1-/lowCD4+FoxP3+ T
cells in peripheral lymph nodes, mesenteric lymph nodes,
spleen, gut, liver and skin. Moreover, CD4+ iNKT cells derived
from NKG2D-/- animals were signiﬁcantly less effective in
preventing acute GVHD lethality (WT vs. NKG2D-/- p¼.003).
Co-injection of CD4+ iNKT cells did not abrogate GVL reactions
of Tcon towards BCL1 cells measured by bioluminescence
imaging (p¼ns). With a-GalCer and IL-2 in vitro expanded
CD4+ iNKT cells had the same protective effect from lethal
acute GVHD compared to freshly isolated CD4+ iNKT cells
(p¼ns). We conclude that low numbers of highly puriﬁed
CD4+ iNKT cells protect from lethal acute GVHD in mice
through a dramatic expansion of donor-derived CD4+FoxP3+
regulatory T cells with retained GVL effect. Despite the fact
that iNKT cells are a rare cell population, the feasibility of in
vitro expansion with retained functionality of CD4+ iNKT cells
provide the basis for clinical translation.
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The role of autophagy in GVHD is unknown.We used a MHC-
disparate allo-HSCT model (B10.BR into B6) and compared
wild-type (WT) vs ATG16L1HM (hypomorphic (HM) for
expression of the ATG16L1 protein) recipients. HM recipients
developed signiﬁcantly increased GVHD mortality (Figure A,
P < 0.001) and morbidity. This was associated with signiﬁ-
cantly increased levels of inﬂammatory cytokines, including
TNF-alpha and IL-12 (P < 0.05). CFSE analysis demonstrated
signiﬁcantly increased proliferation and activation of allor-
eactive donor T cells in HM recipients. Alloreactive donor T
cells in HM recipients expressed higher levels of LPAM-1,
